Phase 3 data suggest PSMA-PET-CT could reduce unnecessary prostate biopsies in selected high-risk men, though longer ...
Temporal evolution of prostate cancer incidence and incidence-based mortality from 2000 to 2022: A retrospective analysis by race and age at diagnosis based on USPSTF screening guidelines. PET ...
MELBOURNE, Australia and INDIANAPOLIS, April 30, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces dosimetry results from the randomized Phase 2 ...
(RTTNews) - Swiss drug major Novartis AG (NVS) announced Monday positive topline results from a pre-specified interim analysis of the Phase III PSMAddition trial for Pluvicto plus hormone therapy in ...
KAWASAKI, Japan, June 11, 2026--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter ...
Insight into the global mortality trends due to prostate cancer among the under-55 population: An analysis of the Global Burden of Disease-2021. This is an ASCO Meeting Abstract from the 2025 ASCO ...
177Lu-PSMA-I&T therapy improved radiographic progression-free survival in metastatic castration-resistant prostate cancer patients. The ECLIPSE trial compared 177Lu-PSMA-I&T with hormone therapy, ...
Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is ...
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results